Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LEXINGTON, MASS., APRIL 10, 2025 (GLOBE NEWSWIRE) -- KEROS THERAPEUTICS, INC. (KEROS OR THE COMPANY) (NASDAQ: KROS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL THERAPEUTICS TO TREAT A WIDE RANGE OF PATIENTS WITH DISORDERS THAT ARE LINKED TO DYSFUNCTIONAL SIGNALING OF THE TRANSFORMING GROWTH FACTOR-BETA (TGF-SS) FAMILY OF PROTEINS,TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE BOARD) HAS DETERMINED TO INITIATE A FORMAL REVIEW PROCESS TO EVALUATE STRATEGIC ALTERNATIVES TO MAXIMIZE STOCKHOLDER VALUE FOR THE COMPANY. IN CONNECTION WITH THIS DETERMINATION, THE BOARD HAS AUTHORIZED THE FORMATION OF A COMMITTEE, CONSISTING OF INDEPENDENT AND DISINTERESTED DIRECTORS, TO OVERSEE THE PROCESS (THE STRATEGIC COMMITTEE) AND MAKE A RECOMMENDATION TO THE FULL BOARD. THE STRATEGIC COMMITTEE, WITH THE ASSISTANCE OF OUTSIDE FINANCIAL AND LEGAL ADVISORS, INTENDS TO CONSIDER A COMPREHENSIVE RANGE OF STRATEGIC ALTERNATIVES, INCLUDING BUT NOT LIMITED TO A SALE OF THE COMPANY OR OTHER BUSINESS COMBINATION TRANSACTION, CONTINUED INVESTMENT IN THE COMPANY'S PIPELINE, AND/OR RETURN OF EXCESS CAPITAL TO STOCKHOLDERS.

KEROS THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES

LEXINGTON, MASS., MARCH 31, 2025 (GLOBE NEWSWIRE) -- KEROS THERAPEUTICS, INC. (KEROS) (NASDAQ: KROS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL THERAPEUTICS TO TREAT A WIDE RANGE OF PATIENTS WITH DISORDERS THAT ARE LINKED TO DYSFUNCTIONAL SIGNALING OF THE TRANSFORMING GROWTH FACTOR-BETA (TGF-SS) FAMILY OF PROTEINS, TODAY ANNOUNCED INITIAL TOPLINE RESULTS FROM THE PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERS. TOPLINE RESULTS FROM THIS ONGOING TRIAL ARE THROUGH THE MULTIPLE ASCENDING DOSE (MAD) TREATMENT PERIOD (DAY 85).

KEROS THERAPEUTICS ANNOUNCES INITIAL TOPLINE RESULTS FROM THE PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERS

LEXINGTON, MASS., FEB. 28, 2025 (GLOBE NEWSWIRE) -- KEROS THERAPEUTICS, INC. (KEROS) (NASDAQ: KROS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL THERAPEUTICS TO TREAT A WIDE RANGE OF PATIENTS WITH DISORDERS THAT ARE LINKED TO DYSFUNCTIONAL SIGNALING OF THE TRANSFORMING GROWTH FACTOR-BETA (TGF-SS) FAMILY OF PROTEINS, TODAY ANNOUNCED THAT KEROS' CHAIR AND CHIEF EXECUTIVE OFFICER JASBIR S. SEEHRA, PH.D., WILL PARTICIPATE AT THE FOLLOWING HEALTHCARE CONFERENCES:

KEROS THERAPEUTICS ANNOUNCES PARTICIPATION AT UPCOMING HEALTHCARE CONFERENCES

LEXINGTON, MASS., FEB. 26, 2025 (GLOBE NEWSWIRE) -- KEROS THERAPEUTICS, INC. (KEROS OR THE COMPANY) (NASDAQ: KROS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL THERAPEUTICS TO TREAT A WIDE RANGE OF PATIENTS WITH DISORDERS THAT ARE LINKED TO DYSFUNCTIONAL SIGNALING OF THE TRANSFORMING GROWTH FACTOR-BETA (TGF-SS) FAMILY OF PROTEINS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024.

KEROS THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 15, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF KEROS THERAPEUTICS, INC. ("KEROS" OR THE "COMPANY") (NASDAQ:KROS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF KEROS THERAPEUTICS, INC. - KROS

NEW YORK , FEB. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF KEROS THERAPEUTICS, INC. ("KEROS" OR THE "COMPANY")(NASDAQ: KROS).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF KEROS THERAPEUTICS, INC. ("KEROS" OR THE "COMPANY") (NASDAQ:KROS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 5, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF KEROS THERAPEUTICS, INC. ("KEROS" OR THE "COMPANY") (NASDAQ:KROS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK , FEB. 4, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF KEROS THERAPEUTICS, INC. ("KEROS" OR THE "COMPANY")(NASDAQ: KROS).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, NY / ACCESS NEWSWIRE / JANUARY 31, 2025 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION OF KEROS THERAPEUTICS, INC. ("KEROS THERAPEUTICS, INC.") (NASDAQ:KROS) CONCERNING POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. KEROS ISSUED A PRESS RELEASE ON DECEMBER 12, 2024, "ANNOUNC[ING] THAT IT HAS VOLUNTARILY HALTED DOSING IN THE 3.0 MG/KG AND 4.5 MG/KG TREATMENT ARMS IN THE ONGOING TROPOS TRIAL, A PHASE 2 CLINICAL TRIAL OF CIBOTERCEPT (KER-012) IN COMBINATION WITH BACKGROUND THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ("PAH"), BASED ON A SAFETY REVIEW DUE TO THE UNANTICIPATED OBSERVATION OF PERICARDIAL EFFUSION ADVERSE EVENTS IN THE TRIAL.

Keros Therapeutics, Inc.

KROS

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

Keros Therapeutics, Inc.

KROS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

KROS